Long time industry leader, Chairman of the
Board Patrick Walsh replaces CEO Bill
Humphries
DURHAM,
N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami
Corporation ("Alcami"), a leading contract development and
manufacturing organization (CDMO), today announced the resignation
of Bill Humphries. Alcami's Board
Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO,
ensuring the continuation of smooth operations and a strong
client-centric approach from a proven industry veteran.
"On behalf of the Board, I'd like to express gratitude to Bill
for his leadership over the last two years during a critical time
of facilities expansion and a global supply chain realignment. He
was a strong advocate for our clients and the organization
benefited from his leadership. I am personally grateful for his
contributions and wish him all the best in his new opportunity,"
commented Walsh.
Mr. Walsh served as CEO of Alcami on two previous occasions and
has served as Chairman over the last four years. In addition to his
duties at Alcami, he currently serves as Chairman of ANI
Pharmaceuticals, Inc. (NASDAQ: ANIP), Chairman of MedPharm, and is
an Operating Partner at Ampersand Capital Partners.
About Alcami
Alcami is a US-based contract development
and manufacturing organization (CDMO) headquartered in NC with 45+
years of experience advancing pharmaceuticals and biologics from
development to delivery. Alcami provides fully integrated lab
services, drug product manufacturing, and cGMP pharma storage and
support services including environmental monitoring, calibration,
and validation. Alcami's private equity ownership includes GHO
Capital, The Vistria Group, and Ampersand Capital Partners. For
more information, please visit alcami.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alcami-announces-ceo-transition-302349441.html
SOURCE Alcami Corporation
